论文部分内容阅读
目的:观察替米沙坦治疗前后对慢性收缩性心衰患者心功能的变化和对患者生活质量的影响。方法:将74例慢性心衰患者在应用洋地黄、β受体阻滞剂、利尿剂基础上随机分为对照组(35例)、治疗组(39例),治疗组给予替米沙坦40 mg/d,对照组给予卡托普利12.5 mg/d,12周后,观察左室射血分数(LVEF)、血浆NT-proBNP水平、明尼苏达心力衰竭生活质量评分。结果:两组治疗后较治疗前LVEF值均明显提高(P<0.05),血浆NT-proBNP水平明显下降(P<0.05),明尼苏达心力衰竭生活质量评分均明显改善(P<0.01),治疗组在LVEF的改善、NT-proBNP水平下降和明尼苏达心力衰竭生活质量评分与对照组相比,差异无统计学意义(P>0.05,且两组均未发现明显不良反应。结论:替米沙坦能显著改善慢性收缩性心衰患者心功能,提高患者生活质量,且安全性高。
Objective: To observe the changes of cardiac function and the quality of life in patients with chronic systolic heart failure before and after treatment with telmisartan. Methods: A total of 74 patients with chronic heart failure were divided into control group (35 cases) and treatment group (39 cases) on the basis of digitalis, β blockers and diuretics. The treatment group was treated with Telmisartan 40 mg / d, and control group was given captopril 12.5 mg / d. After 12 weeks, the left ventricular ejection fraction (LVEF), plasma NT-proBNP level and the quality of life of heart failure patients in Minnesota were observed. Results: Compared with before treatment, LVEF in both groups were significantly increased (P <0.05), plasma NT-proBNP levels were significantly decreased (P <0.05), heart failure quality of Minnesota patients were significantly improved (P <0.01) There was no significant difference between the improvement of LVEF, the decrease of NT-proBNP and the quality of life of heart failure in Minnesota compared with the control group (P> 0.05), and no adverse reactions were found in both groups.Conclusion: Telmisartan Significantly improve cardiac function in patients with chronic systolic heart failure, improve patient quality of life, and high safety.